SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system.

IF 10.8 1区医学 Q1 NEUROSCIENCES

Translational Neurodegeneration Pub Date : 2024-08-09 DOI:10.1186/s40035-024-00431-y

Jiaqi Mei, Yi Li, Liyan Niu, Ruikai Liang, Mingyue Tang, Qi Cai, Jingdong Xu, Deju Zhang, Xiaoping Yin, Xiao Liu, Yunfeng Shen, Jianping Liu, Minxuan Xu, Panpan Xia, Jitao Ling, Yuting Wu, Jianqi Liang, Jing Zhang, Peng Yu

{"title":"SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system.","authors":"Jiaqi Mei, Yi Li, Liyan Niu, Ruikai Liang, Mingyue Tang, Qi Cai, Jingdong Xu, Deju Zhang, Xiaoping Yin, Xiao Liu, Yunfeng Shen, Jianping Liu, Minxuan Xu, Panpan Xia, Jitao Ling, Yuting Wu, Jianqi Liang, Jing Zhang, Peng Yu","doi":"10.1186/s40035-024-00431-y","DOIUrl":null,"url":null,"abstract":"<p><p>The rising prevalence of diabetes mellitus has casted a spotlight on one of its significant sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for diabetes management, are increasingly studied for their cognitive benefits. These benefits may include reduction of oxidative stress and neuroinflammation, decrease of amyloid burdens, enhancement of neuronal plasticity, and improved cerebral glucose utilization. The multifaceted effects and the relatively favorable side-effect profile of SGLT2 inhibitors render them a promising therapeutic candidate for cognitive disorders. Nonetheless, the application of SGLT2 inhibitors for cognitive impairment is not without its limitations, necessitating more comprehensive research to fully determine their therapeutic potential for cognitive treatment. In this review, we discuss the role of SGLT2 in neural function, elucidate the diabetes-cognition nexus, and synthesize current knowledge on the cognitive effects of SGLT2 inhibitors based on animal studies and clinical evidence. Research gaps are proposed to spur further investigation.</p>","PeriodicalId":23269,"journal":{"name":"Translational Neurodegeneration","volume":"13 1","pages":"41"},"PeriodicalIF":10.8000,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11312905/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Neurodegeneration","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40035-024-00431-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

The rising prevalence of diabetes mellitus has casted a spotlight on one of its significant sequelae: cognitive impairment. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally developed for diabetes management, are increasingly studied for their cognitive benefits. These benefits may include reduction of oxidative stress and neuroinflammation, decrease of amyloid burdens, enhancement of neuronal plasticity, and improved cerebral glucose utilization. The multifaceted effects and the relatively favorable side-effect profile of SGLT2 inhibitors render them a promising therapeutic candidate for cognitive disorders. Nonetheless, the application of SGLT2 inhibitors for cognitive impairment is not without its limitations, necessitating more comprehensive research to fully determine their therapeutic potential for cognitive treatment. In this review, we discuss the role of SGLT2 in neural function, elucidate the diabetes-cognition nexus, and synthesize current knowledge on the cognitive effects of SGLT2 inhibitors based on animal studies and clinical evidence. Research gaps are proposed to spur further investigation.

查看原文本刊更多论文

SGLT2 抑制剂：通过对神经系统的多方面影响治疗认知障碍的新型疗法。

糖尿病发病率的上升使人们开始关注糖尿病的一个重要后遗症：认知障碍。钠-葡萄糖共转运体-2（SGLT2）抑制剂最初是为治疗糖尿病而开发的，现在越来越多的人开始研究它对认知的益处。这些益处可能包括减少氧化应激和神经炎症、减少淀粉样蛋白负荷、增强神经元可塑性以及改善脑葡萄糖利用率。SGLT2 抑制剂的多方面作用和相对较好的副作用使其成为治疗认知障碍的理想候选药物。然而，SGLT2 抑制剂在认知障碍方面的应用并非没有局限性，有必要进行更全面的研究，以充分确定其在认知治疗方面的治疗潜力。在这篇综述中，我们讨论了 SGLT2 在神经功能中的作用，阐明了糖尿病与认知之间的关系，并根据动物实验和临床证据综合了目前有关 SGLT2 抑制剂对认知影响的知识。同时还提出了一些研究空白，以促进进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Neurodegeneration Neuroscience-Cognitive Neuroscience

CiteScore

19.50

自引率

0.80%

发文量

审稿时长

10 weeks

期刊介绍： Translational Neurodegeneration, an open-access, peer-reviewed journal, addresses all aspects of neurodegenerative diseases. It serves as a prominent platform for research, therapeutics, and education, fostering discussions and insights across basic, translational, and clinical research domains. Covering Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions, it welcomes contributions on epidemiology, pathogenesis, diagnosis, prevention, drug development, rehabilitation, and drug delivery. Scientists, clinicians, and physician-scientists are encouraged to share their work in this specialized journal tailored to their fields.